Compare Robinhood Markets, Inc. (HOOD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs GeneDx Holdings Corp — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Robinhood Markets, Inc. is far larger — about 47.6× GeneDx Holdings Corp's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and GeneDx Holdings Corp for 19 Days on average.
| HOOD | WGS | |
|---|---|---|
Market Cap | $96.21B | $2.02B |
Volume | 22,572,153 | 734,640 |
Sector | Financials | Health |
52-Week High | $147.08 | $167.51 |
52-Week Low | $65.16 | $34.51 |
Typical Hold Time | 75 Days | 19 Days |
Enterprise Value | $102.75B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, as the stock consolidates near pivot point support at $107. The company shows strong fundamental momentum with revenue growing from $3.0B in 2024 to $4.5B in 2025 and net income reaching $1.88B. Recent announcements include plans for 24/7 stock trading and expanded product offerings, positioning the company for continued growth in the expanding e-brokerage market.
HOOD presents a compelling growth story with robust profitability metrics and analyst optimism, though elevated valuation ratios and execution risks warrant caution. The stock's technical setup suggests near-term consolidation with upside potential toward the $137.53 consensus price target, supported by strong institutional sentiment and innovative business initiatives.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
